Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Summary

This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Heart Failure and Impaired Kidney Function

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 130 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

AstraZeneca

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites